KR101320261B1 - Wisp 활성의 조절 및 검출을 위한 방법 및 조성물 - Google Patents
Wisp 활성의 조절 및 검출을 위한 방법 및 조성물 Download PDFInfo
- Publication number
- KR101320261B1 KR101320261B1 KR1020077023542A KR20077023542A KR101320261B1 KR 101320261 B1 KR101320261 B1 KR 101320261B1 KR 1020077023542 A KR1020077023542 A KR 1020077023542A KR 20077023542 A KR20077023542 A KR 20077023542A KR 101320261 B1 KR101320261 B1 KR 101320261B1
- Authority
- KR
- South Korea
- Prior art keywords
- wisp
- cells
- polypeptide
- antibody
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/105,876 US7455834B2 (en) | 2002-06-29 | 2005-04-14 | Methods and compositions for modulating and detecting WISP activity |
| US11/105,876 | 2005-04-14 | ||
| PCT/US2006/014008 WO2006113402A1 (en) | 2005-04-14 | 2006-04-13 | Methods and compositions for modulating and detecting wisp activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080003344A KR20080003344A (ko) | 2008-01-07 |
| KR101320261B1 true KR101320261B1 (ko) | 2013-10-22 |
Family
ID=36809580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077023542A Expired - Fee Related KR101320261B1 (ko) | 2005-04-14 | 2006-04-13 | Wisp 활성의 조절 및 검출을 위한 방법 및 조성물 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7455834B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1869086B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4979684B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101320261B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101198623B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006236649B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0612184A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2604933C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2388993T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL186095A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007012798A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20075825L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ561709A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2412201C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006113402A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200708738B (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7455834B2 (en) * | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| BR112014019741A2 (pt) | 2012-02-11 | 2020-12-22 | Genentech, Inc | Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado |
| KR20150134346A (ko) * | 2013-03-27 | 2015-12-01 | 지이 헬스케어 에이에스 | 진단 조성물을 제조하기 위한 방법 및 시약 |
| CN106456732A (zh) * | 2014-04-15 | 2017-02-22 | 索伦托治疗有限公司 | 结合wisp1的抗体疗法 |
| KR102011366B1 (ko) * | 2016-11-17 | 2019-10-14 | 연세대학교 산학협력단 | 암 전이 억제제의 스크리닝 방법 |
| EP4365299A3 (en) * | 2018-05-17 | 2024-08-07 | Olives Biotherapeutics Inc. | Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021998A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| WO2001053486A1 (en) | 1999-03-08 | 2001-07-26 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| WO2004003158A2 (en) | 2002-06-29 | 2004-01-08 | Genentech, Inc. | Methods and compositions for modulating and detecting wisp activity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US7455834B2 (en) | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
| JP2007505131A (ja) | 2003-09-11 | 2007-03-08 | ジェネンテック・インコーポレーテッド | Wispアンタゴニストの使用方法 |
-
2005
- 2005-04-14 US US11/105,876 patent/US7455834B2/en not_active Expired - Lifetime
-
2006
- 2006-04-13 AU AU2006236649A patent/AU2006236649B2/en not_active Ceased
- 2006-04-13 MX MX2007012798A patent/MX2007012798A/es active IP Right Grant
- 2006-04-13 BR BRPI0612184A patent/BRPI0612184A8/pt active Search and Examination
- 2006-04-13 CA CA2604933A patent/CA2604933C/en not_active Expired - Fee Related
- 2006-04-13 NZ NZ561709A patent/NZ561709A/en not_active IP Right Cessation
- 2006-04-13 WO PCT/US2006/014008 patent/WO2006113402A1/en not_active Ceased
- 2006-04-13 JP JP2008506722A patent/JP4979684B2/ja not_active Expired - Lifetime
- 2006-04-13 KR KR1020077023542A patent/KR101320261B1/ko not_active Expired - Fee Related
- 2006-04-13 RU RU2007142005/10A patent/RU2412201C2/ru not_active IP Right Cessation
- 2006-04-13 ZA ZA200708738A patent/ZA200708738B/xx unknown
- 2006-04-13 EP EP06750127A patent/EP1869086B1/en not_active Expired - Lifetime
- 2006-04-13 CN CN2006800215473A patent/CN101198623B/zh not_active Expired - Lifetime
- 2006-04-13 ES ES06750127T patent/ES2388993T3/es not_active Expired - Lifetime
-
2007
- 2007-09-20 IL IL186095A patent/IL186095A/en not_active IP Right Cessation
- 2007-11-13 NO NO20075825A patent/NO20075825L/no not_active Application Discontinuation
-
2008
- 2008-10-20 US US12/254,649 patent/US7732567B2/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999021998A1 (en) | 1997-10-29 | 1999-05-06 | Genentech, Inc. | Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3 |
| WO2001053486A1 (en) | 1999-03-08 | 2001-07-26 | Genentech, Inc. | Compositions and methods for the treatment of tumor |
| WO2004003158A2 (en) | 2002-06-29 | 2004-01-08 | Genentech, Inc. | Methods and compositions for modulating and detecting wisp activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101198623A (zh) | 2008-06-11 |
| ES2388993T3 (es) | 2012-10-22 |
| IL186095A (en) | 2012-10-31 |
| CA2604933C (en) | 2014-07-08 |
| CN101198623B (zh) | 2013-06-12 |
| AU2006236649A2 (en) | 2008-07-24 |
| IL186095A0 (en) | 2008-01-20 |
| ZA200708738B (en) | 2009-01-28 |
| BRPI0612184A8 (pt) | 2017-12-26 |
| US7732567B2 (en) | 2010-06-08 |
| NZ561709A (en) | 2009-12-24 |
| AU2006236649A1 (en) | 2006-10-26 |
| CA2604933A1 (en) | 2006-10-26 |
| AU2006236649B2 (en) | 2012-03-29 |
| JP2008537958A (ja) | 2008-10-02 |
| MX2007012798A (es) | 2007-11-20 |
| HK1112470A1 (en) | 2008-09-05 |
| EP1869086A1 (en) | 2007-12-26 |
| US20060147453A1 (en) | 2006-07-06 |
| RU2007142005A (ru) | 2009-05-20 |
| KR20080003344A (ko) | 2008-01-07 |
| RU2412201C2 (ru) | 2011-02-20 |
| JP4979684B2 (ja) | 2012-07-18 |
| EP1869086B1 (en) | 2012-07-18 |
| WO2006113402A1 (en) | 2006-10-26 |
| BRPI0612184A2 (pt) | 2011-12-20 |
| NO20075825L (no) | 2008-01-11 |
| US20090148448A1 (en) | 2009-06-11 |
| US7455834B2 (en) | 2008-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6960485B2 (ja) | 線維芽増殖因子受容体2に対するモノクローナル抗体 | |
| JP5611047B2 (ja) | アクチビンレセプター様キナーゼ−1アンタゴニスト組成物とその使用方法 | |
| JP2007515949A (ja) | スクリーニングアッセイ及び腫瘍治療の方法 | |
| JP2013256535A (ja) | 血管の発達を調節するための、egfl7アンタゴニストを含む組成物および方法 | |
| US7732567B2 (en) | Methods and compositions for modulating and detecting wisp activity | |
| JP4636497B2 (ja) | Wisp活性を調節し検出するための方法及び組成物 | |
| JP2007505131A (ja) | Wispアンタゴニストの使用方法 | |
| ES2349162T3 (es) | Procedimientos y composiciones para modular y detectar la actividad de wisp. | |
| US20110159588A1 (en) | Methods for Modulating a PDGF-AA Mediated Biological Response | |
| HK1112470B (en) | Methods and compositions for modulating and detecting wisp activity | |
| JP4166254B2 (ja) | ボールカインポリペプチド及び核酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20160929 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170929 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20181015 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20181015 |